Nicox Sa · EURONEXT:ALCOX
Nicox Sa — Investor Presentation (March 2025)
31 slides from Nicox Sa's investor presentation, Mar 6, 2025
Slide 1: Nicox Corporate Presentation
Nicox Corporate Presentation An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health March 6,.2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to, an
Slide 3: Latest News: First Commercial Sale of ZERVIATE in China
Latest News: First Commercial Sale of ZERVIATE in China New Revenue Stream for Nicox First Commercial Launch from the Nicox- Ocumension Collaboration Product Launch Quickly After Approval Thanks to a Rapid Manufacturing Campaign at Ocumension’s State-of-the-Art Factory Royalties from 5% to 9% on Net
Slide 4: 2025 Opportunities Building on 2024 Achievements
2025 Opportunities Building on 2024 Achievements Strategic Horizons a4 qa 48 NN NNN Appointment of Gavin Spencer as Chief Executive Officer Nicox Board entirely renewed with appointment of Damian Marron as Chair and 3 new Board members Restructuring of debt agreements with BlackRock Streamlining cos
Slide 5: Consistently Delivering Innovations in Ophthalmology
Consistently Delivering Innovations in Ophthalmology ... Development >» A potentially differentiated profile targeting ~$6bn worldwide glaucoma market > Positive results from the first Phase 3 trial’, Mont Blanc, demonstrating competitive Intraocular Pressure (IOP) Lowering properties > Additional b
Slide 6: Upcoming Milestones
Upcoming Milestones Several Positive Milestones in 2025 NCX 470 “* Whistler results — Q2 2025 “ Denali results — Q3 2025 “ Estimated potential worldwide sales over $300 million! ZERVIATE “ Royalty and milestones revenue Corporate “ Ongoing partnership discussions “+ Potential NCX 1728 license option
Slide 7: Revenue Sold to Soleus Capital in October 2024
Revenue Sold to Soleus Capital in October 2024 First Commercial Sale in China in Q4 2024
Slide 8: Glaucoma: a Worldwide Ophthalmic Condition with Unmet Medical Needs
Glaucoma: a Worldwide Ophthalmic Condition with Unmet Medical Needs Elevated IOP* Contributes to Irreversible Optic Nerve Damage, Leading to Progressive Vision Loss normal aqueous humor outflow \ vitreous: anterior chamber ens —+ optic nerve head posterior chamber healthy eye chamber damage to the o
Slide 9: Unmet Medical Needs for Glaucoma Treatment
Unmet Medical Needs for Glaucoma Treatment Y¥ 40% of patients do not achieve their target IOP on existing monotherapies' V Tolerability issues with some medications lead to discontinuations, Despite having well established first-line therapies, including the standard-of-care, latanoprost, patients d
Slide 10: NCX 470 Lowers IOP Through a Validated Dual Mechanism Pathway
NCX 470 Lowers IOP Through a Validated’ Dual Mechanism Pathway Clinically Validated with the First NO-Donating PGA, VYZULTA® Two Pathways for Primary or conventional Aqueous Humor outflow normally Outflow accounts for ~60% to 80% of outflow anterior laaaes * | °) chamber ~ NCX 470 posterior chamber
Slide 11: Positive NCX 470 Mont Blanc Topline Results
Positive NCX 470 Mont Blanc Topline Results! Phase 3 Clinical Program Intended to Support U.S. & China NDA Submissions Designed to demonstrate safety and efficacy of NCX 470 0.1% vs. Latanoprost 0.005%, studies will evaluate reduction of IOP from time-matched baseline at pre-established time points
Slide 12: Mont Blanc dosage arms schematic
1. This schematic reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial
Slide 13: Mont Blanc IOP reduction results
As published in the landmark EMGT study “…each mmHg of decreased IOP was related to an approximately 10% lowering [of risk of vision loss progression]”1 1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design
Slide 14: NCX 470 0.1% vs Latanoprost 0.005% IOP data
NCX 470 0.1%: N = 328 Latanoprost 0.005%: N = 333 • Denotes statistically significant differences vs latanoprost (p<0.049) • Fechtner et al., AJO, published, 2024 - https://doi.org/10.1016/j.ajo.2024.03.002
Slide 15: Statistically significant differences vs latanoprost
• * * * * • • * Denotes statistically significant differences vs latanoprost (p<0.049)
Slide 16: NCX 470 Was Well Tolerated
• • • • ≤ • • ≤ • • NCX 470 Was Well • • • 1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial.
Slide 17: NCX 470 Presentations at Key Ophthalmology Conferences
NCX 470 - Presentations at Key Ophthalmology Conferences AMERICAN GLAUCOMA SOCIETY + Poster: Diurnal IOP Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC Trial oa CECE + Poster 1: Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum o
Slide 18: Authors' Conclusion on NCX 470 0.1%
Authors’ Conclusion: The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important
Slide 19: NCX 1728 Initial Exploratory Studies Generated Encouraging Results
Initial Exploratory Studies Generated Encouraging Results Next Steps 1. Bastia et al., J Ocul Pharmacol Ther. 2022, 38: 496-504; 2. Sgambellone et al., Transl Vis Sci Technol. 2023, 1;12(9):22.
Slide 20: U.S. Glaucoma Clinical Advisory Board with Leading Experts
U.S. Glaucoma Clinical Advisory Board with Leading Experts DR. ROBERT D. FECHTNER, MD, CHAIRMAN Professor and Chair of the Department of Ophthalmology at SUNY Upstate Medical University, Syracuse, NY DR. SANJAY G. ASRANI, MD Professor of Ophthalmology at Duke University in Durham, North Carolina, an
Slide 21: Value Proposition of NCX 470
Value Proposition of NCX 470 < fe} S 2 Novel molecule with competitive positive impact on lowering IOP, the leading cause of glaucoma Positive pivotal Phase 3 topline results from the Mont Blanc trial.23 First non-combination product to demonstrate statistical non-inferiority to a prostaglandin anal
Slide 22: NCX 470 patents and peak sales potential
*Assuming a partnership or obtaining appropriate financing • Composition of matter patent to 2029 expected to be extended to 2034 in the United States and formulation patent to 2039. Additional marketing exclusivity may be available based on the status as a New Chemical Entity • Peak annual net sale
Slide 23: Ocumension Therapeutics partner profile
Portfolio of 25 Listed on the 444 Employees, Based in China Products with Hong Kong Stock Including 232 in Created in 2018 10 Commercialised Exchange Since Commercial Dedicated to $34 Million 2020 Ophthalmology Revenue in 2023 $600 Million (+55%) Market Cap • • •
Slide 24: Kowa partner profile
Founded in Japan in 1894 ~8000 Employees The Pharmaceutical Team of Medical Active Worldwide with an Annual Sector is an Representatives in Multiple Group Revenue of Important One with in Japan and a Domains Including $4.9 Billion an International Franchise in Life Sciences Presence Glaucoma • • •
Slide 25: Future Commercialization of NCX 470
Future Commercialization of NCX 470 To Secure the Long-Term Future of the Company = The Company is considering a number of options to ensure the commercialization of NCX 470 and concretize the future strategy: * New license agreements * — Joint venture structures with companies having complementary
Slide 26: Existing Commercial Products: VYZULTA and ZERVIATE
.) Existing Commercial Products VYZULTA BAUSCH +LOMB v 5% to 9% royalties on annual net sales in China 0] OcuMension v Potential for up to $17.2 million in sales milestones by Ocumension Kk Ww P 4 P q v Manufactured by Ocumension in their state-of-the art Chinese factory First Commercial Sale in Chi
Slide 27: NCX 1728 mechanism of action
• • • • MOA = Mechanism of Action GTP = guanosine triphosphate sGC = soluble guanylate cyclase cGMP = cyclic guanosine monophosphate, PKG – protein kinase G ER = endoplasmic reticulum Ca++ = Calcium
Slide 28: A Refocused Global Leadership Team
A Refocused Global Leadership Team NA Gavin Spencer Sandrine Gestin Doug Hubatsch Emmet Purtill Chief Executive Officer VP, Finance and HR EvP, Chief Scientific Officer VP Business Development th NOVARTIS t Novartis oe COVANCE~ coors eu Alcon INTERNATIONAL Sonia Benhamida Observer Damian Marron Chri
Slide 29: Financial Highlights
Financial Highlights Cash Balance Expected to Support Current Operations into Q4 2025 Financial Position and Ownership of the Nicox Group’ Cash, Cash Equivalents as at 31 December 2024 €10.7 million Long Term Debt as at 31 December 2024 €15.1 million Cash Runway? Q4 2025 Outstanding Shares? 69.4 mil
Slide 30: Investment Highlights
Investment Highlights v_A Proven Track Record in Clinical Development and Business Development * Two product approvals in the U.S., one in China * Business Development deals in the U.S., Japan, China, and globally with Tier 1 companies v NCX 470, a Derisked, Late-Stage Development Program * Positive
Slide 31: Nicox S.A.
31 Nicox S.A. Sundesk Sophia Antipolis Emerald Square Batiment C rue Evariste Galois, 06410 Biot, France T: +33 (0)4 97 24 53 00 nicox visible science COMMUN ications@ nicox.com WWww.nicox.com, (@